12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Company News  |  Deals

Calypso Biotech, iDD Biotech deal

iDD Biotech granted Calypso exclusive, worldwide rights to CALY-002, a humanized mAb, to treat refractory celiac disease. iDD received an upfront payment and is eligible for milestones, plus royalties....

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >